Tempest Therapeutics, Inc. (NASDAQ:TPST) was held by 1 institutional investor that filed 13F reports for the quarter ended June 30, 2026.
At the end of Q2 2026, this holder held 1.69% of Tempest Therapeutics' outstanding shares, down from 1.88% in Q1 2026.
Total holdings of TPST shares were unchanged from Q1 2026, and the holder count was unchanged from Q2 2025.
The one institutional holder owned 269.77K shares of Tempest Therapeutics at the end of Q2 2026, unchanged from the prior quarter and unchanged from a year earlier.
Versant Venture Management, LLC held the largest position in TPST at 269.77K shares as of June 30, 2026, or 1.69% of shares outstanding.